Tilrekimig for moderate-to-severe eczema in teens and adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 3 interventional trial compares tilrekimig with dupilumab and placebo in adults and adolescents with moderate-to-severe atopic dermatitis. Participants are randomly assigned in a 2:2:1 ratio during a 24-week initial treatment period to receive tilrekimig, dupilumab, or placebo, followed by continued assessment up to 52 weeks. The study will evaluate safety, tolerability, and how the treatment affects the skin and symptoms over time. Key eligibility includes age 12 or older, chronic eczema for at least a year, and insufficient response to topical therapies. Primary locations are research sites in Birmingham, AL, and Phoenix, AZ, with Pfizer as lead sponsor.

Why it matters

Who can join: the full rules

Key Inclusion Criteria

* You are \[12\] years of age or older
* You have had moderate-to-severe eczema for at least 1 year
* Topical medicines for eczema have not worked well for you

Key Exclusion Criteria

* Clinically Significant Autoimmune Disease
* Significant Infection History or Active Infection
* Known or Suspected Immunodeficiency/Immunosuppression
* Significant psychiatric illness or suicidality
* Clinically significant hepatic, renal, or hematologic abnormalities

Where it's running

• AllerVie Clinical Research
  Birmingham, Alabama, United States Recruiting
• Alliance Dermatology & MOHS Center
  Phoenix, Arizona, United States Recruiting
• Dermatology Trial Associates, Inc.
  Bryant, Arkansas, United States Recruiting
• Kern Research, Inc.
  Bakersfield, California, United States Recruiting
• Marvel Clinical Research
  Huntington Beach, California, United States Recruiting
• Avance Clinical Trials
  Laguna Niguel, California, United States Recruiting

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults

  A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.

  Recruiting at 4 sites Phase 3 Arcutis Biotherapeutics, Inc. · Birmingham, Alabama and 3 other locations · NCT07916480

• Nocturnal ScratchSense ring: test of automatic scratch detection in adults with itchy skin

  This study tests whether the Replior ScratchSense ring can accurately detect and measure nighttime scratching in adults with itchy skin conditions.

  Recruiting Replior AB · Grenoble · NCT07909967

• ADBest TREAT Registry for adults with atopic dermatitis

  A registry in Germany is collecting real-world data from adults with atopic dermatitis to see how treatments are used and how the disease affects quality of life.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg · NCT07904546

• How lebrikizumab affects the skin microbiome and mycobiome in adults with atopic dermatitis

  This study looks at whether lebrikizumab changes the skin bacteria, fungi, and specifically Staphylococcus species, in adults with moderate-to-severe atopic dermatitis.

  Recruiting University Hospital Bispebjerg and Frederiksberg · Copenhagen · NCT07807228

• QX-4533 safety study in healthy volunteers and people with moderate-to-severe atopic dermatitis

  This study tests the safety and tolerability of QX-4533, given as a pill, in healthy adults and in patients with moderate-to-severe atopic dermatitis to see how the drug behaves in the body and what side effects may occur.

  Recruiting Phase 1 QuantX Biosciences US Inc. · Shanghai, Shanghai Municipality · NCT07800104

• TRIV-573 for moderate to severe atopic dermatitis in adults

  This study tests whether TRIV-573 can help adults with moderate to severe atopic dermatitis and checks its safety.

  Recruiting at 17 sites Phase 2 Triveni Bio · Fountain Valley, California and 16 other locations · NCT07782333

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.